<DOC>
	<DOCNO>NCT02256449</DOCNO>
	<brief_summary>A multicentre , observational , prospective device registry , control group , design evaluate efficacy safety bioresorbable coronary device , use accord indication use , daily clinical practice consecutive number patient undergoing PCI de novo coronary artery lesion . A total 1,500 patient plan include registry .</brief_summary>
	<brief_title>REPARA Study : REgistry PAtients With bioResorbable Device Daily Clinical prActice</brief_title>
	<detailed_description>The patient include consecutively site one year . They individual sex , require endovascular intervention meeting authorise criterion indication use device use dual anti-platelet therapy ( DAPT ) aspirin thienopyridines consider . STUDY OBJECTIVES To evaluate MACE rate implantation bioresorbable coronary device patient de novo coronary artery lesion , follow-up 12 month perform . Primary objective : MACE rate 12 month follow-up : Cardiac death Myocardial infarction TLR driven ischaemia lesion treat region 5 mm proximally distally site implantation device ( ID-TLR ) . Secondary objective : - Angina - Death due cause . - Myocardial infarction type ( MI : QMI , NQMI , TV , NTV ) - All TLR drive ischaemia - All TVR drive ischaemia . - All coronary revascularisations perform ( PCI v CABG ) - Device thrombosis ( acute , sub-acute , late ) evidence ( definitive , probable , possible ) . - Immediate success device . - Immediate success procedure . - Rate patient DAPT &lt; 1 month , 1-3 month , 3-6 month , 6-12 month relationship occurrence event - Composite endpoint : Cardiac death , TV-MI ID-TLR : ( Target Lesion Failure ( TLF ) ) Cardiac death , myocardial infarction ( MI ) ID-TVR : ( Target Vessel Failure ( TVF ) ) - Rate overlap device : characteristic relationship occurrence event - Collection image data case , accord judgement investigator , intravascular imaging test perform ( IVUS , OCT ) .</detailed_description>
	<criteria>Patient must least 18 year age time sign Informed Consent Form Patient treat de novo coronary lesion native coronary artery amenable receive bioresorbable device The length treat lesion inferior nominal length device ( 12 mm , 18 mm , 28 mm ) reference vessel diameter &gt; 2 mm &lt; 3,8 mm . The patient relative contraindication double antiplatelet therapy , aspirin indefinitely thienopyridine least 6 month Cardiogenic shock Left main disease Aortocoronary graft Intrastent restenosis Potentially childbearing woman contraceptive method Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Coronary artery disease ; angioplasty ; bioresorbable device</keyword>
</DOC>